Pfizer’s pursuit of AstraZeneca was hanging by a thread yesterday after its “final” ￡69.4bn offer was rejected by the UK company, sparking recriminations between the rival drugmakers and shareholders.
輝瑞(Pfizer)對阿斯利康(AstraZeneca)的收購昨日懸于一線，此前該公司提出的694億英鎊“最終”收購要約被阿斯利康拒絕，引發這兩家互為競爭對手的制藥商及其股東間的相互攻訐。
您已閱讀20%（294字），剩余80%（1157字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。